Business context and reporting period
Option Care Health, Inc. filed this Form 10-K for the fiscal year ended December 31, 2020. It provides home and alternate-site infusion services through 145 locations in 45 states and operates as one infusion-services segment. The filing also reports unaudited fourth-quarter results.
Financial performance and liquidity
| Metric | FY 2020 | FY 2019 |
|---|---|---|
| Revenue | $3,032.6 million | $2,310.4 million |
| Gross profit / margin | $682.3 million / 22.5% | $513.0 million / 22.2% |
| Operating income (loss) | $110.8 million | $(0.3) million |
| Net loss | $(8.1) million | $(75.9) million |
| Operating cash flow | $127.4 million | $39.5 million |
| Cash at year-end | $99.3 million | $67.1 million |
Revenue increased 31.3%; the comparison is not like-for-like because 2019 included BioScrip only from the August 6, 2019 merger date, while 2020 included it for the full year. Management cited organic therapy growth as an additional contributor. Acute-therapy revenue was flat year over year, while chronic-therapy revenue grew in the mid-teens. Gross margin improved 0.3 percentage points; SG&A declined to 16.5% of revenue from 19.9%.
In Q4 2020, revenue was $804.7 million, gross profit $183.8 million, operating income $44.3 million, and net income $17.8 million. Net income was positive in Q3 and Q4, following losses in the first two quarters.
At year-end, working capital was $223.0 million. Principal debt outstanding was $1,161.5 million ($915.8 million first-lien term loan and $245.8 million second-lien notes); reported debt net of discount and financing costs was $1,124.4 million. The ABL facility had no borrowings and $165.4 million net availability. The company prepaid $174.0 million of second-lien principal during 2020, funded in part by a stock offering that generated $118.9 million net proceeds. Capital expenditures were $26.9 million. The company reported no off-balance-sheet arrangements.
Material changes and unusual items
- Management said it fully achieved its target of at least $60 million in net merger cost synergies, through administrative streamlining, network optimization, and procurement savings.
- Interest expense rose to $107.8 million from $73.7 million, reflecting merger-related debt; debt prepayments partly offset the increase. A $11.5 million debt-extinguishment loss was recorded in 2020.
- The company received $11.7 million in CARES Act relief in Q2 and returned it to the federal government in Q3, citing spending reductions and integration synergies.
- In January 2021, a new $250 million first-lien term loan was used to repay the remaining $245.8 million second-lien balance. The amendment reduced the first-lien spread, but added debt and incurred fees and prepayment penalties.
Outlook, risks, and contingencies
Management stated that available cash and expected operating cash flows should cover operating needs for at least the next 12 months, while noting that additional financing may be needed for longer-term plans or acquisitions. The filing provides no numerical revenue or earnings guidance. Management could not confidently forecast the duration or ultimate financial effect of COVID-19.
COVID-19 reduced new acute and chronic referrals but increased transfers from hospital and outpatient settings. Staffing inefficiencies and higher personal-protective-equipment costs pressured operations; management reported no material deceleration in collections and adequate supply levels at year-end. Key risks include payer pricing and reimbursement changes, dependence on referral and pharmaceutical-supplier relationships, concentration of 70% of supply purchases among three vendors, labor availability, extensive healthcare regulation, and cybersecurity and privacy exposure.
Debt leverage and variable interest rates remain significant risks. A 100-basis-point rate change was estimated to affect annual interest expense by $6.4 million, considering year-end debt and swaps. UnitedHealth Group represented approximately 15% of 2020 revenue; direct government programs represented approximately 15%. The company disclosed ongoing legal proceedings but said it did not expect pending matters, after reserves and indemnification, to materially affect its balance sheet; adverse outcomes could still affect earnings or cash flows. The auditor gave unqualified opinions on the financial statements and internal controls; revenue transaction-price adjustments were identified as a critical audit matter.
Important facts for investors to verify
- Assess underlying organic growth separately from the full-year contribution of the 2019 BioScrip merger, and examine acute versus chronic therapy trends.
- Verify that reported merger synergies are sustainable and that margin gains persist despite labor, supply, and reimbursement pressures.
- Review debt terms, interest-rate exposure, required repayments, and the effects of the January 2021 refinancing and second-lien repayment.
- Monitor payer concentration, supplier concentration, collection estimates, and the critical audit matter concerning revenue transaction-price adjustments.
- Track COVID-19 effects on referrals, staffing, supplies, and cash conversion, as well as the outcome of disclosed legal matters.
- Consider ownership and dilution: HC Group Holdings I held about 63.6% at year-end; after a February 2021 secondary offering it held about 54%. The company said it did not anticipate paying cash dividends in the foreseeable future.